PO.CL05.02 · 临床研究

用腺病毒 E4ORF-1 工程化的代谢超级增强型 NK 细胞

Metabolically supercharged NK cells engineered with adenoviral E4ORF-1

海报缩略图:用腺病毒 E4ORF-1 工程化的代谢超级增强型 NK 细胞
编号 5197 展板 15 时间 4/21 09:00–12:00 区域 Section 40 主讲 May Daher, MD
分会场 Adoptive Cell Therapy 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Maliha Munir1, Madison Moore1, Silvia Tiberti1, Rafet Basar1, Byron Jia1, Leen Kheirbek1, Nadima Uprety1, Francia Reyes Silva1, Rejeena Shrestha1, Ana K. Nunez Cortes1, Mayra Shanley1, Sunil Acharya2, Jeong-Min Park1, Bin Liu1, Pinaki Banerjee1, Paul Lin1, Donghai Xiong1, Enli Liu1, Alia Ghrayeb1, Eyal Gottlieb1, Elizabeth Joan Shpall3, Katayoun Rezvani1, May Daher1

1UT MD Anderson Cancer Center, Houston, TX,2Molecular and Cellular Oncology, UT MD Anderson Cancer Center, Houston, TX,3Professor of Medicine, Dept. of Stem Cell Transplant & Cell Therapy, UT MD Anderson Cancer Center, Houston, TX

摘要 Abstract

中文摘要
背景:嵌合抗原受体(CAR)T 细胞和自然杀伤(NK)细胞在血液系统恶性肿瘤中取得了成功,但在实体瘤中疗效有限。一个主要障碍是代谢上敌对的实体瘤微环境(TME),其中缺氧、酸中毒和营养缺乏损害了免疫细胞的适应性、细胞毒性和持久性。当前增强单一营养物摄取或靶向单一代谢途径的代谢工程策略仅提供部分益处,且仍易受肿瘤代谢可塑性的影响。一个关键的未满足需求是开发具有代谢灵活性而非单一途径依赖性的免疫细胞。为解决这一问题,我们探索了一种受病毒代谢重连启发的策略。在腺病毒感染期间,病毒蛋白 E4ORF-1 激活 PI3K-AKT 信号传导、稳定 MYC、增强营养物摄取,并增强糖酵解、氧化磷酸化(OXPHOS)和脂肪酸氧化(FAO)。我们假设将 E4ORF-1 工程化到 NK 细胞中会产生一种类病毒的代谢状态,能够耐受实体瘤中的营养限制。 方法:代谢表征包括线粒体质量和膜电位、Seahorse 检测和 SCENITH。将 CAR-NK 细胞与实体瘤细胞系共培养,使用 xCelligence 和 IncuCyte 平台定量细胞毒性。在血液系统(MOLM14)和实体瘤(SKOV3)异种移植模型中测试体内疗效。机制研究纳入 bulk RNAseq、CyTOF 分析和 AMPK 的 CRISPR-Cas9 敲除。 结果:E4ORF-1 表达在多种肿瘤模型中显著增强了 NK 细胞的抗肿瘤功能,并在葡萄糖、谷氨酰胺或脂质受限条件下维持了细胞毒性和代谢适应性。蛋白质印迹证实了糖酵解、OXPHOS 和 FAO 中营养转运蛋白和代谢酶的协调上调。E4ORF-1 NK 细胞在靶向代谢抑制下也保持了细胞毒性优势;尽管糖酵解、OXPHOS、FAO 或谷氨酰胺代谢被阻断,它们始终表现出更优的肿瘤杀伤,凸显了增强的代谢适应性。转录组分析显示,即使在营养限制下或肿瘤攻击后,细胞因子信号传导和代谢特征仍得以保留。机制研究确定 AMPK 为 E4ORF-1 表型所需的核心代谢整合因子,因为 CRISPR 删除 AMPK 消除了代谢和功能优势。将 E4ORF-1 纳入 CAR-NK 细胞改善了体内的肿瘤控制和生存。 结论:E4ORF-1 增强了 NK 细胞的代谢灵活性,实现了持续的抗肿瘤活性并改善了对实体瘤的治疗潜力。这些发现确立了病毒基因介导的代谢重连作为一个有前景的平台,可增强 CAR-NK 细胞的适应性并克服 TME 中的营养竞争。
查看英文原文 English abstract
Background: Chimeric antigen receptor (CAR) T and natural killer (NK) cells have achieved success in hematologic malignancies but show limited efficacy in solid tumors. A major barrier is the metabolically hostile solid tumor microenvironment (TME), where hypoxia, acidosis, and nutrient deprivation impair immune cell fitness, cytotoxicity, and persistence. Current metabolic engineering strategies that enhance single nutrient uptake or target one metabolic pathway provide only partial benefit and remain vulnerable to tumor metabolic plasticity. A critical unmet need is the development of immune cells with metabolic flexibility rather than single-pathway dependence. To address this, we explored a strategy inspired by viral metabolic rewiring. During adenoviral infection, the viral protein E4ORF-1 activates PI3K-AKT signaling, stabilizes MYC, augments nutrient uptake, and enhances glycolysis, oxidative phosphorylation (OXPHOS), and fatty acid oxidation (FAO). We hypothesized that engineering E4ORF-1 into NK cells would generate a viral-like metabolic state capable of withstanding nutrient restriction in solid tumors. Methods: Metabolic characterization included mitochondrial mass and membrane potential, Seahorse assays, and SCENITH. CAR-NK cells were cocultured with solid tumor cell lines, and cytotoxicity was quantified using xCelligence and IncuCyte platforms. In vivo efficacy was tested in xenograft models of hematologic (MOLM14) and solid tumors (SKOV3). Mechanistic studies incorporated bulk RNAseq, CyTOF profiling, and CRISPR-Cas9 knockout of AMPK. Results: E4ORF-1 expression significantly enhanced NK cell antitumor function across tumor models and sustained cytotoxicity and metabolic fitness under glucose-, glutamine-, or lipid-limited conditions. Western blotting confirmed coordinated upregulation of nutrient transporters and metabolic enzymes across glycolysis, OXPHOS, and FAO. E4ORF-1 NK cells also maintained a cytotoxic advantage under targeted metabolic inhibition; despite blockade of glycolysis, OXPHOS, FAO, or glutamine metabolism, they consistently demonstrated superior tumor killing, underscoring enhanced metabolic adaptability. Transcriptomic profiling showed preserved cytokine signaling and metabolic signatures even under nutrient restriction or after tumor challenge. Mechanistic studies identified AMPK as a central metabolic integrator required for the E4ORF-1 phenotype, as CRISPR deletion of AMPK abrogated metabolic and functional advantages. Incorporation of E4ORF-1 into CAR-NK cells improved tumor control and survival in vivo. Conclusion: E4ORF-1 enhances NK cell metabolic flexibility, enabling sustained antitumor activity and improving therapeutic potential for solid tumors. These findings establish viral gene-mediated metabolic rewiring as a promising platform to strengthen CAR-NK cell fitness and overcome nutrient competition in the TME.
利益披露 Disclosure
L. Kheirbek, None.. S. Acharya, None.. A. Ghrayeb, None.. E. Gottlieb, None. M. Daher, Takeda Patent. Aurigene SAB member. Bruker Cellular Analysis Other, SAB member. CellsBin Other, SAB member.

← 返回 AACR 2026 检索